<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/26408213-3715-441C-86D1-8477DDBBE281"><gtr:id>26408213-3715-441C-86D1-8477DDBBE281</gtr:id><gtr:name>Benaroya Research Inst at Virginia Mason</gtr:name><gtr:address><gtr:line1>1201 Ninth Avenue</gtr:line1><gtr:postCode>98101-2795</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Gene and Cell Based Therapy</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/26408213-3715-441C-86D1-8477DDBBE281"><gtr:id>26408213-3715-441C-86D1-8477DDBBE281</gtr:id><gtr:name>Benaroya Research Inst at Virginia Mason</gtr:name><gtr:address><gtr:line1>1201 Ninth Avenue</gtr:line1><gtr:postCode>98101-2795</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3F6B1AC6-DD52-444A-B404-C8B1B0321044"><gtr:id>3F6B1AC6-DD52-444A-B404-C8B1B0321044</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:otherNames>Serena</gtr:otherNames><gtr:surname>Longhi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902288"><gtr:id>43CAF18D-0ABB-4590-A2B2-5876B0A5BD6D</gtr:id><gtr:title>Autoantigen-specific regulatory T-cells: a new tool for tolerance induction in autoimmune hepatitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902288</gtr:grantReference><gtr:abstractText>CD4+CD25+ regulatory T-cells (T-regs) control immune system over-reaction. Autoimmune hepatitis (AIH) is a severe liver disorder, affecting children and adults, whose immune system attacks components of the liver having failed to recognise them as self. AIH is seen six-fold more frequently in children referred to our specialised centre than 10 years ago. Patients with AIH need life-long immunosuppression, despite which they often progress to transplant-requiring end-stage liver disease. In AIH T-regs are impaired in number and function. These cells can, however, be expanded and their function boosted in the test tube, thus providing a potential therapeutic option to halt the autoimmune attack. I plan to investigate complementary approaches to generate and expand functional T-regs from AIH patients in the laboratory to obtain them in sufficient numbers to be used as a novel and more specific mode of treatment. The safety of these cells will be tested in mice. The information obtained will be important not only for AIH, but also for other disabling autoimmune disorders, collectively representing 5% of human disease. All facilities required for the clinical application of this project are available within the KCL Division of Gene and Cell based Therapy at King?s College Hospital.</gtr:abstractText><gtr:technicalSummary>Autoimmune hepatitis (AIH) is a severe liver disorder requiring life-long immuno-suppressive treatment, which may cause serious side-effects and despite which transplant-requiring end-stage liver disease may occur. Due to its frequently acute presentation, AIH offers the unique opportunity to follow the evolution of liver damage from the very onset to cirrhosis and/or transplantation. 
The involvement of autoreactive B, CD4 and CD8 T-cells in AIH is well documented with the three arms of the immune response converging on discrete antigenic regions. We have provided evidence that this multipronged immune attack is associated to a numerical and functional impairment of regulatory CD4+CD25+ T-cells (T-regs), a cell subset central to immune-tolerance. Though functionally inefficient, T-regs from patients with AIH can expand in number and augment their suppressor function when exposed to high dose interleukin-2 and anti-CD3/anti-CD28 T-cell expander. T-regs expanded for up to 4 weeks maintain phenotypic characteristics of the original T-regs, such as the forkhead-winged helix transcription factor BOX P3 (FOXP3) and suppress much more efficiently than freshly isolated T-regs. Using the same approach I also succeeded in obtaining T-regs from CD4+CD25- T-cells, a subset mainly composed of effectors, but also including a proportion of cells with regulatory potential. T-reg ability to expand and to suppress has been mainly investigated in a non-antigen-specific setting. There is evidence, and I have supporting preliminary data, that antigen-specific suppress more efficiently than non-antigen-specific T-regs. AIH provides an ideal model for the generation and potential therapeutic use of antigen-specific T-regs, as the autoantigenic targets are known. Using different approaches I propose to generate and expand antigen-specific T-regs from CD4+CD25+ and CD4+CD25- T-cells. The goal is to generate and expand cells with therapeutic potential due to their ability of delivering suppressive signals to effectors of the autoimmune attack. I will investigate whether T-regs maintain their functional commitment over time. To this end I will focus on a subset of T-regs expressing the ecto-enzyme CD39, a molecule recently proposed as marker of T-reg ?stability?. As a first step towards clinical application, I will test the safety of patients-derived antigen-specific T-regs following injection into NOD/SCID/gamma mice and I will evaluate their survival in vivo. If successful, this study would provide proof-of-principle for the feasibility of tolerance induction not only in AIH but also in other autoimmune disorders, collectively representing 5% of the human disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>947965</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Autoimmune Hepatitis Consortium</gtr:description><gtr:id>547C5EDD-7F83-4BBE-822E-EE6C51B4EEAC</gtr:id><gtr:impact>Performed determination of gene expression profile on liver biopsy samples</gtr:impact><gtr:outcomeId>544b98ff612847.30255153-1</gtr:outcomeId><gtr:partnerContribution>Creating a blood and tissue bank where samples (and data generated from their analysis) can be accessed and used</gtr:partnerContribution><gtr:piContribution>Participation in prospective follow-up cohort studies, GWAS, eQTL and Epigenetics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beth Israel Deaconess Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Transplant Immunology</gtr:department><gtr:description>Role of CD39 in T-reg and Th17 plasticity</gtr:description><gtr:id>7418F862-3A45-46F1-8978-65F3EA8DB659</gtr:id><gtr:impact>One of the mentors at BIDMC is co-author in six peer-review papers (PMID: 22387392, 23787765, 23292173, 25042541, 25034284, 24681654 and 27210814), senior author in three peer-review papers (PMID: 22965858, 25172498 and 24505337) and senior author in 6 abstracts that have been accepted as oral presentation and poster at the Annual Meeting of the American Association of Immunologists (Boston, 4-8 May 2012), the European Congress of Immunology (Glasgow, 5-8 September 2012), the Digestive Disease Week (Orlando, 18-21 May 2013 and Chicago, 3-6 May 2014), the American Association for the Study of Liver Diseases (Boston, 9-13 November 2013). The poster presented at the DDW 2013 was awarded 'poster of distinction'.</gtr:impact><gtr:outcomeId>fHb9biAFVSd-1</gtr:outcomeId><gtr:partnerContribution>The study I have being doing at BIDMC (Boston, USA) as part of my MRC Clinician Scientist Fellowship complements a parallel investigation carried out by my team and focusing on the stability of both polyclonal and antigen-specific regulatory T-cells. My mentors at BIDMC have provided the equipment and the consumables for the 12-month project I have been carrying out in their laboratory.</gtr:partnerContribution><gtr:piContribution>I initially spent 12 months at BIDMC (Harvard) to investigate the role of CD39 in governing the plasticity of T-regs and Th17 cells and how this plasticity can be modulated by the cytokine environment. The period spent at BIDMC to work on this project has been very productive. I have found that the level of expression of CD39 ectonucleotidase confers regulatory T-cell properties (high levels of FOXP3 and ability to suppress target cell effector function) to effector Th17 cells limiting their pathogenicity. I have also found that these CD39-expressing Th17 cells exist ex vivo and are numerically decreased in Crohn's patients compared to healthy subjects both in the circulation and in the lamina propria. As part and continuation of this project I am now testing mechanisms involved in the regulation of CD39 expression in both T-reg and Th17 cells in vitro and in vivo.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>T-reg cell immunotherapy in autoimmune disease and transplantation</gtr:description><gtr:id>5C293009-8769-4417-8855-9E665158D319</gtr:id><gtr:impact>One of the PIs I have been collaborating with was sponsor of my MRC Clinician Scientist Fellowship and, as such, he has followed my research and academic progress. 
The MRC Transplantation Centre statistician I have been collaborating with has been co-applicant in project grant applications.</gtr:impact><gtr:outcomeId>QXpJyBoRuUt-1</gtr:outcomeId><gtr:partnerContribution>I have been collaborating with senior scientists and PIs of the MRC Transplantation Centre/Division of Transplantation Immunology and Mucosal Biology (King's College London) and of the Division of Immunology, Infection and Inflammatory Disease (King's College London) within the 'Enhanced cell therapy for cancer, autoimmunity and transplantation' programme. Regular meetings and workshops are carried out within this programme, the activity of which has been very useful in fostering the translational component of my research aiming at developing a T-reg based immunotherapy for the treatment/cure of autoimmune hepatitis. Within the programme I have been also collaborating with the statistician of the MRC Transplantation Centre. The contribution this collaboration has given to my research has been remarkable both at the level of study design and statistical approach to deploy.</gtr:partnerContribution><gtr:piContribution>During the meetings carried out within the Cell Therapy programme we have been presenting research data and discussing protocols for isolation, generation and expansion of regulatory T-cells under GMP conditions.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Benaroya Research Institute at Virginia Mason (BRI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Tetramer Core Laboratory</gtr:department><gtr:description>HLA-class II tetramers and autoimmune hepatitis</gtr:description><gtr:id>FC4C37B7-80D2-4D2F-A994-56B368C68C25</gtr:id><gtr:impact>The collaboration on the above mentioned project has led to the publication of one research article (PMID: 21274874).</gtr:impact><gtr:outcomeId>i8QQ9FnjzGM-1</gtr:outcomeId><gtr:partnerContribution>The Benaroya Tetramer Facility Center has provided tetramers of HLA-DR7 and HLA-DR3/CYP2D6 peptides for studying antigen-specific CD4 T-cell immune responses in autoimmune hepatitis type 2. The class II tetramers have also been utilised to isolate and characterise antigen-specific regulatory T-cells. Tetramers of HLA-DR7 or HLA-DR3 and influenza hemagglutinin (HA) peptides have been also constructed and used as controls.</gtr:partnerContribution><gtr:piContribution>The use of HLA-DR7 and HLA-DR3/CYP2D6 tetramers has enabled us to enumerate antigen-specific CD4 T-cells in HLA-DR7 and DR3 positive patients with AIH-2. We have used the HLA-class II tetramers also for isolating CYP2D6-specific regulatory T-cells in the same disease context and further characterize their phenotypic and functional profile, including their ability to suppress and produce cytokines. We are currently using the HLA-DR7 and HLA-DR3-CYP2D6 tetramers to isolate antigen specific T-regs from patients with autoimmune hepatitis and subsequently expand them under GMP conditions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Federation of Immunological Societies travel grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>European Federation of Immunological Societies (EFIS)</gtr:fundingOrg><gtr:id>362F725E-9FD4-4E96-BAEB-5B264C17B348</gtr:id><gtr:outcomeId>bTYH4VrLQbD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1950</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EASL travel grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>European Association for the Study of the Liver (EASL)</gtr:fundingOrg><gtr:id>6541778B-66AF-4D6B-8195-E9EEA27522C6</gtr:id><gtr:outcomeId>esJqqFptv1p</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KCL Travel grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>37F8E2AB-A854-46C3-8132-ED7CDE484BA9</gtr:id><gtr:outcomeId>oqrmj2AAHbc0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EASL Travel Grant</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>European Association for the Study of the Liver (EASL)</gtr:fundingOrg><gtr:id>1D407922-6ADF-4AA0-ACDF-EEDA02FE231A</gtr:id><gtr:outcomeId>Km5ciGnigaG</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BASL Travel grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>British Association for the Study of the Liver (BASL)</gtr:fundingOrg><gtr:id>3BCFE1DD-8A27-4F17-84FD-B64869621E66</gtr:id><gtr:outcomeId>inGZyC2feBs0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>695</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI Travel grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>0E713B39-5433-4A4A-BA98-FE5B6A629F87</gtr:id><gtr:outcomeId>o8TTuTX9XdJ0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>King's Health Partners Research and Development Challenge Fund</gtr:department><gtr:description>Research Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>King?s Health Partners</gtr:fundingOrg><gtr:id>D602FCC3-7E19-412C-92F6-8801D2C24229</gtr:id><gtr:outcomeId>qXaT59B4GUh</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75546</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's College Hospital Charity PhD studentship</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>King's College Hospital NHS Foundation Trust (NCH)</gtr:fundingOrg><gtr:id>C6D5C463-2A9D-40D3-A83B-2CE5EC378A64</gtr:id><gtr:outcomeId>Cw6feU2ncZL0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI Travel Grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>5B7CD161-5DE3-4950-AEB8-5F28ED16878B</gtr:id><gtr:outcomeId>544a8b712bac08.79547900</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46208</gtr:amountPounds><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Foundation for Science and Technology</gtr:department><gtr:description>PhD studentship/Doctoral grant</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>New University of Lisbon</gtr:fundingOrg><gtr:id>924CA156-4F95-4FC0-994A-48C4F797B4D0</gtr:id><gtr:outcomeId>S6f6bFGP4250</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dame Sheila Sherlock Travel Fellowship</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Royal College of Physicians of London</gtr:fundingOrg><gtr:id>8509AED8-4154-4303-B29D-6C966B254355</gtr:id><gtr:outcomeId>Q5BAE1KgQBc</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI Travel grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>FE1F0563-458A-40B9-A8CA-7B10BBFDB886</gtr:id><gtr:outcomeId>VqDNu9X3r9F0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>CYP2D6-specific regulatory T cell lines are generated from CD14neg cells exposed to high dose IL-2, T-cell expander and CYP2D6 peptides. Following 8-10 days CD4posCD25high T-regs are purified and then co-cultured for additional two days with semi-mature dendritic cells, obtained from monocytes following exposure to GMCSF, IL-4, IFN lambda and CYP2D6 peptides. This protocol has been published in two research articles (PMID: 21274874 and 24566085) and has now been modified in order to be used under GMP conditions.</gtr:description><gtr:id>3D40971E-F14D-4388-AB8B-3B420C68F49E</gtr:id><gtr:impact>In the past 12 months further work has been done in order to define the phenotype, function and expansion ability of antigen-specific T-reg cell lines obtained using GMP instead of research-grade reagents. Important data have been obtained with regard to the function and stability of these cells.</gtr:impact><gtr:outcomeId>D9tsM8SgrTp</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CYP2D6 T-reg cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21274874</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C377700B-84A6-4169-BEC3-461B7C21F626</gtr:id><gtr:title>Human CD4+CD25(high)CD127 (low/neg) regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0365edbe56308ff190297a56ecb12733"><gtr:id>0365edbe56308ff190297a56ecb12733</gtr:id><gtr:otherNames>Su H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>YASPZhwS7no</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1419E42D-5C92-4777-8F1C-38C805782E67</gtr:id><gtr:title>Autoimmune hepatitis after liver transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>hwofLPEapZY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>116875C5-9C95-4808-8E12-26491820A659</gtr:id><gtr:title>Autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3a37063525ad4ecaac899b68014b3eb"><gtr:id>e3a37063525ad4ecaac899b68014b3eb</gtr:id><gtr:otherNames>Heneghan MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_12627_27_23768844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8B7C559-E1B0-4537-BFD0-E83E42356DCC</gtr:id><gtr:title>Purinergic signaling in liver disease.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52440cb3044a4ffe9cd4d054726785a1"><gtr:id>52440cb3044a4ffe9cd4d054726785a1</gtr:id><gtr:otherNames>Vaughn BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>544a847ff13ec1.38292794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51E9BA2-B3CA-44FC-A79B-500F6C7A3581</gtr:id><gtr:title>Inhibition of interleukin-17 promotes differentiation of CD25? cells into stable T regulatory cells in patients with autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_12627_27_22387392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44D3D19D-E9BB-4268-9481-7AB121159555</gtr:id><gtr:title>Immunosuppressive drugs affect interferon (IFN)-? and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5a2fd690f19521.77434133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>080BFA46-1CE5-45CC-AF88-FD7E50AB64ED</gtr:id><gtr:title>Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives.</gtr:title><gtr:parentPublicationTitle>Journal of pediatric gastroenterology and nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d744b37eab5d54815ab8dca6c36aae5"><gtr:id>5d744b37eab5d54815ab8dca6c36aae5</gtr:id><gtr:otherNames>Wang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-2116</gtr:issn><gtr:outcomeId>544a859911bfd7.45557730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>552170F3-E6F7-4C2B-9B6F-70EC7D2F831B</gtr:id><gtr:title>Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/217e862c10aaef1a63bf86e2391c99dd"><gtr:id>217e862c10aaef1a63bf86e2391c99dd</gtr:id><gtr:otherNames>Holder BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>544a851ba60052.49138059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48EE0EDF-588C-43C0-BBE4-194AA7EA8E09</gtr:id><gtr:title>Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions.</gtr:title><gtr:parentPublicationTitle>Autoimmunity reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1568-9972</gtr:issn><gtr:outcomeId>56a9a8b68b4ed8.29672370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B30F090-4E28-445B-BBC7-A93876C255A8</gtr:id><gtr:title>Reply: To PMID 23787765.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>544a845b1a7537.81610440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2D23C3-D5A8-48BD-B463-0A3B01BD7962</gtr:id><gtr:title>CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb5108252a7c492285e862bee9acbbfd"><gtr:id>cb5108252a7c492285e862bee9acbbfd</gtr:id><gtr:otherNames>Doherty GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_12627_27_22965858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A79C984F-C4F3-48F0-A2D9-763ADF90E6F9</gtr:id><gtr:title>CD39 and CD161 modulate Th17 responses in Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a13b521ad50adb257cbf8dd02528735"><gtr:id>3a13b521ad50adb257cbf8dd02528735</gtr:id><gtr:otherNames>Bai A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>544a842b98f9b6.90394689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EEB281D-2289-41C6-9E38-5A3FB4B29B03</gtr:id><gtr:title>In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56af75f9ceec01.12420800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0415290B-087E-46C0-A2C9-2A155AEB6FBE</gtr:id><gtr:title>Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8f5d399f2e0a6ebfa31bf2fd8143506"><gtr:id>b8f5d399f2e0a6ebfa31bf2fd8143506</gtr:id><gtr:otherNames>Carey I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>HiRmBkwhK4a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A302114E-B567-45B1-B3A2-F87261515247</gtr:id><gtr:title>Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease.</gtr:title><gtr:parentPublicationTitle>IUBMB life</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1521-6543</gtr:issn><gtr:outcomeId>56a9a947a7c2a1.19866306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FF1F5DA-F690-4D26-ACE1-9EBF8AB8937B</gtr:id><gtr:title>Diagnostic criteria of autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Autoimmunity reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1568-9972</gtr:issn><gtr:outcomeId>544a8563844e06.33344751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969E99E6-6535-4229-A1F3-11CE44816D60</gtr:id><gtr:title>CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>5894adca487571.11969753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BB490FE-0800-48A7-B1C4-554F9308365D</gtr:id><gtr:title>T-regs in autoimmune hepatitis-systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>pm_12627_27_23287048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8B4A5E4-919D-4218-8BE9-95C6B64EAC07</gtr:id><gtr:title>Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663d8014cef8ffb02f4a605f921fa784"><gtr:id>663d8014cef8ffb02f4a605f921fa784</gtr:id><gtr:otherNames>Ham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>544a84a86f20c7.34347121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F966BD4A-18D6-44F6-A4EE-DE729DCA71E6</gtr:id><gtr:title>Regulatory T cells in autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_12627_27_22748772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79B42840-5C40-481B-B939-AFF0124855DF</gtr:id><gtr:title>The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_12627_27_22371007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>570F1E6A-A910-4628-8230-FF0E49ACDC36</gtr:id><gtr:title>Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_12627_27_23787765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A3B9B27-B5C7-4132-A2E7-BFCA3225F4A8</gtr:id><gtr:title>Autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Current pediatric reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1573-3963</gtr:issn><gtr:outcomeId>56a9a893255667.10155338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07622A4D-1756-4F3C-A983-17D757D7EC1E</gtr:id><gtr:title>Pathogenesis of autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1521-6918</gtr:issn><gtr:outcomeId>pm_12627_27_22117632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F662F6E-E25C-4EF2-8A76-79F52AED5335</gtr:id><gtr:title>Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>Jnt5zK5EGWE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E999392B-2620-4B69-90EF-6D9E6EE4959F</gtr:id><gtr:title>Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.</gtr:title><gtr:parentPublicationTitle>Journal of molecular medicine (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0946-2716</gtr:issn><gtr:outcomeId>pm_12627_27_23292173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7077FDF4-C988-48E7-B885-AA5B73EB7A48</gtr:id><gtr:title>Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544a853d54a772.20465173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0073F601-D24F-41FC-9F85-5BC0229C1D85</gtr:id><gtr:title>The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17c7099b1b184f40f2eaedd0a248f5b6"><gtr:id>17c7099b1b184f40f2eaedd0a248f5b6</gtr:id><gtr:otherNames>Muratori L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>pm_12627_27_23871639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AD76C46-72CD-4753-9355-3286740BADBF</gtr:id><gtr:title>Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a74eaf20df091.86640357</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902288</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>